Hjem › Mantelcellelymfom
Mantelcellelymfom kliniske forsøg rekrutterer i USA
70 studier for Mantelcellelymfom rekrutterer deltagere på steder over hele USA.
Byer med flest studier
- Baldwin Park, CA15 studier
- Houston, TX15 studier
- Durham, NC13 studier
- Milwaukee, WI12 studier
- Seattle, WA12 studier
- New York City, NY12 studier
- Boston, MA11 studier
- Columbus, OH11 studier
- Nashville, TN11 studier
- Chicago, IL10 studier
- Portland, OR9 studier
- Rochester, MN9 studier
- St. Louis, MO8 studier
- Atlanta, GA8 studier
- Denver, CO8 studier
- Mountain View, CA7 studier
- Cleveland, OH7 studier
- Los Angeles, CA7 studier
- Dallas, TX6 studier
- Salt Lake City, UT6 studier
- Miami, FL6 studier
- Jacksonville, FL6 studier
- Ann Arbor, MI6 studier
- Buffalo, NY5 studier
- Kansas City, MO5 studier
- Charlotte, NC5 studier
- Tampa, FL5 studier
- Baltimore, MD5 studier
- New Haven, CT5 studier
- Washington, DC5 studier
- Edison, NJ5 studier
- Philadelphia, PA5 studier
- San Diego, CA5 studier
- Providence, RI4 studier
- Minneapolis, MN4 studier
- Pittsburgh, PA4 studier
- Charlottesville, VA4 studier
- Queens, NY4 studier
- Cedar Rapids, IA4 studier
- Richmond, VA4 studier
Efter delstat
- Alabama4 studier
- Arizona6 studier
- Californien29 studier
- Colorado10 studier
- Connecticut6 studier
- Delaware3 studier
- Florida16 studier
- Georgia9 studier
- Illinois10 studier
- Indiana4 studier
- Iowa5 studier
- Kansas7 studier
- Kentucky4 studier
- Louisiana3 studier
- Maryland9 studier
- Massachusetts13 studier
- Michigan8 studier
- Minnesota14 studier
- Missouri8 studier
- Nebraska4 studier
- New Jersey8 studier
- New York16 studier
- North Carolina17 studier
- Ohio16 studier
- Oregon9 studier
- Pennsylvania9 studier
- Rhode Island4 studier
- Tennessee12 studier
- Texas19 studier
- Utah6 studier
- Virginia7 studier
- Washington14 studier
- Wisconsin13 studier
Nyligt opdaterede studier
Officiel studietekst (engelsk)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
RekruttererFase 3
Alder 60 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT05976763Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
RekruttererObservationsstudie
Alder 18 til 110 · Alle køn · Opdateret 2. okt. 2026 · NCT05724121Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT07763210Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06252675A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06542250The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07285044A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06742996A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06697184Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT06553872Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT06784167A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT06029309Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07003295Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT06564038A Study of ARC-02 in B-cell NHL
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 26. aug. 2026 · NCT07691606Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 17. aug. 2026 · NCT07673367AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT06340737Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
RekruttererFase 1
Alder 18 til 85 · Alle køn · Opdateret 10. aug. 2026 · NCT05887167Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
RekruttererFase 1/2
Alder 13 til 90 · Alle køn · Opdateret 6. aug. 2026 · NCT06533579LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RekruttererFase 1
Alder 18 til 81 · Alle køn · Opdateret 6. aug. 2026 · NCT05990465Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT06675123A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 30. jul. 2026 · NCT07424833This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 24. jul. 2026 · NCT07121946Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.